Metabolix, the USA based producer of PHA biopolymers carries out a manufacturing site assessment including a capital plan, engineering study, site owner’s interview, cost estimate operations and intermediate level biopolymer production. The company has planned to defer commitment for contract production at the site. With the plan of significant improvement in output of Mirel PHA biopolymers, the main objective of this deal will revolve around the production of a-PHA biopolymer that will be utilized in current development plans for the unique PHA product.

Read more about this plan here - http://www.bioplasticsmagazine.com/en/news/meldungen/20141228Metabolix-focus-on-a-PHA.php

According to the statement of Joseph Shaulson, CEO of Metabolix, the company believes that biopolymer production is the best approach at this time. As the company expects increase in output from the pilot facilities, it is important to keep the capital investment at the modest level this year and enhance the runway offered by finance and restructure accomplished already. Further, same approach is supposed to work well for speeding the availability of a-PHA material to develop market.  Joseph further adds that the company needs to work upon a strong strategy going further towards evaluation and development of production expansion ideas for the business. This is important for the company with the idea of bringing on production of PHA on wide level.